In this issue:
More vs less intensive BP lowering in CKD
Early de-escalation of antiplatelets after PCI
Dual vs triple antithrombotic therapy after PCI
Cost-effectiveness of the PCSK9 inhibitor evolocumab
Antiplatelet treatment after PCI in patients with impaired renal function
Intracoronary bone marrow cell transfer after MI
Gut microbe-generated TMAO as a cardiovascular risk biomarker
Visit-to-visit BP variability and cardiovascular outcomes
Glycaemic control and major coronary events in type 1 diabetics
Death and cardiac arrest in U.S. triathlon participant
Please login below to download this issue (PDF)